Nexstim raises € 1.75 million via a directed issue of new shares to London-based investor City Financial - Funds to be used to support beginning the commercialisation of its NBT® system
Helsinki, Finland: 25 October 2017 - Nexstim Plc (NXTMH:HEX, NXTMS:STO), a medical technology company developing and marketing pioneering navigated non-invasive brain stimulation systems for both therapeutic and diagnostic applications, announces that it is raising new equity financing of the gross amount € 1.75 million via a directed issue of new shares to a London-based fund managed by City Financial Investment Company Limited.
The company's Board of Directors resolved to issue up to 7,000,000 new shares at a subscription price of € 0.25 per share, resulting in an aggregate subscription price of € 1,750,000 (before any expenses relating to the share issue). The new shares will be issued based on an authorisation received at the company's Annual General Meeting on 28 March 2017.
More info on Nexstim's website.
Next > Lexogen and Bluebee partner to bring the SLAMseq metabolic RNA sequencing data analysis pipeline to the users
Previous > Sequana Medical announces results of the MOSAIC trial data presented at 2017 AASLD